Business
MicroBlate Fine's first in-human use update
MicroBlate Fine's first in-human use update.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0192C\n Creo Medical Group PLC\n 16 June 2021\n \n \n \n \n \n \n \n Creo Medical Group plc\n \n \n (\"Creo\" or the \"Company\")\n \n \n \n \n \n MicroBlate Fine's first in-human use update \n \n \n \n \n \n Life-changing FDA cleared Creo device successful in adding months to patient's life expectancy and well-being \n \n \n \n \n \n Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, provides an update on its 510(k) US Food & Drug Administration ('FDA') cleared tissue ablation device MicroBlate™ Fine. \n \n \n \n \n \n First in-human use update\n \n \n \n \n \n Further to the announcement dated 9 December 2020, the device was successfully used for \n the first in-human, minimally invasive, Endoscopic Ultrasound (EUS) guided, treatment in a patient with an unresectable pancreatic neuroendocrine tumour. The procedure was performed by Dr. Carlos Robles-Medranda at Instituto Ecuatoriano de Enferemdades Digestives (\"IECED\"), Ecuador and the resulting outcome was successful. With a condition that was not possible to be treated surgically using traditional methods, the patient required a less invasive treatment in order to potentially prolong the patient's life. The Company is delighted to report that, following the procedure using \n MicroBlate™ \n Fine\n , the patient remains well and is enjoying life. \n Subsequent scans of the patient's pancreas continue to confirm the treatment's durability.\n \n \n \n \n \n Led By Dr. Carlos Robles-Medranda, IECED \n is the most advanced Gastroenterology and Digestive Endoscopy centre in Latin America and is endorsed by the World Endoscopy Organization (WEO) which leads the promotion of Endoscopy throughout the world. When asked about his experience with the MicroBlate\n ™\n Fine\n , Dr Carlos Robles-Medranda stated: \"I am excited about the potential of this technology for use in EUS guided therapy; the microwave energy allows me to precisely target and ablate difficult lesions. I believe this technology will have a positive impact on my patients, and I will continue to offer this treatment option.\"\n \n \n \n \n \n MicroBlate™ Fine\n , was the third device to gain FDA regulatory clearance within Creo's portfolio of flexible end...